Development of Lipid-Based Nanoparticles for In Vivo Targeted Delivery of Imaging Agents into Breast Cancer Cells
Annual rept. 15 Sep 2008-14 Sep 2009
PENNSYLVANIA UNIV PHILADELPHIA
Pagination or Media Count:
Breast cancer represents a unique disease in oncology, in that specific markers have been identified and are routinely used for diagnosis and targeted therapy. Targeted delivery of a combined imaging and therapy agent to cancer cells is an avenue to develop a new generation of effective and selective anticancer agents. The goal of this proposal is to develop novel nanoparticles for in vivo breast cancer targeting. The nanoparticles consist of a cholesterol ester core surrounded with a lipid monolayer shell containing an imaging agent and metal chelating groups that can attach proteins of interest through specific His6 tagging. Thus far we have synthesized nanoparticle building blocks as well as imaging agents optimized nanoparticles core composition that provides the minimum nanoparticles size of 8 nm found out that shell loaded image is much more effective than core loaded one. We have prepared a number of lipid nanoparticles with His6-tagged targeting proteins, which were successfully tested in vitro for optical imaging of model cell lines. We have developing lipid nanoparticles, which are loaded with optical and MR imaging agents and coordinationally bound with different ligands for targeting HER-2neu on breast cancer cells. In near future we will test these nanoparticles with SK-BR-3 HER-2neu and MDA-MD-468 HER-2neu- breast cancer cell lines.
- Anatomy and Physiology
- Medicine and Medical Research